Epidemiology of Pulmonary Embolism

ABSTRACT

The diagnosis of venous thromboembolism (VTE) has notoriously been challenging because the disease often has no specific clinical presentation, can at times be completely asymptomatic, and can masquerade as other illnesses. To further complicate matters, the rules for coding VTE in the presence of other illnesses changed in 1983 so that among patients who died of VTE and other causes, VTE was omitted from the coding. The International Cooperative Pulmonary Embolism Registry enrolled 2,454 consecutive pulmonary embolism (PE) patients from 52 participating hospitals in 7 countries. The aim was to establish the 3-month all-cause mortality rate and to identify factors associated with death. Three-month follow-up was completed in 98% of the patients. The all-cause mortality rate was 11.4% during the first 2 weeks after diagnosis and 17.4% at 3 months. Especially troubling among survivors was the high rate of recurrent VTE after anticoagulation was discontinued. Age is a potent risk factor for the development of VTE. The two most common genetic mutations that predispose to VTE are the factor V Leiden and the prothrombin gene. VTE can be precipitated by oral contraceptives, pregnancy, or hormone replacement therapy.

KEYWORD

Epidemiology - pulmonary embolism - deep vein thrombosis

REFERENCES

• 1 Goldacre M J, Roberts S, Yeates D, Griffith M. Hospital admission and mortality rates for venous thromboembolism in Oxford region, UK, 1975-98.  Lancet . 2000;  355 1968-1969
• 2 Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Étude de la Thrombose de Bretagne Occidentale.  Thromb Haemost . 2000;  83 657-660
• 3 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton III J L. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.  Arch Intern Med . 1998;  158 585-593
• 4 Goldhaber S Z, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER).  Lancet . 1999;  353 1386-1389
• 5 Nakamura M, Fujioka H, Yamada N. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research.  Clin Cardiol . 2001;  24 132-138
• 6 Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod A F. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score.  Thromb Haemost . 2000;  84 548-552
• 7 Heit J A, Mohr D N, Silverstein M D, Petterson T M, O'Fallon W M, Melton III L J. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study.  Arch Intern Med . 2000;  160 761-768
• 8 Hansson P O, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors.  Arch Intern Med . 2000;  160 769-774
• 9 Douketis J D, Foster G A, Crowther M A, Prins M H, Ginsberg J S. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy.  Arch Intern Med . 2000;  160 3431-3436
• 10 van Aken B E, den Heijer M, Bos G M, van Deventer J S, Reitsma P H. Recurrent venous thrombosis and markers of inflammation.  Thromb Haemost . 2000;  83 536-539
• 11 Silverstein M D, Heit J A, Mohr D N, Petterson T M, O'Fallon W M, Melton L J. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study.  Arch Intern Med . 1998;  158 585-593
• 12 Eekhoff E M, Rosendaal F R, Vandenbroucke J P. Minor events and the risk of deep venous thrombosis.  Thromb Haemost . 2000;  83 408-411
• 12a Lapostolle F, Surget V, Borron S W. Severe pulmonary embolism associated with air travel.  N Engl J Med . 2001;  345 779-783
• 13 Bendz B, Rostrup M, Sevre K, Andersen T O, Sandset P M. Association between acute hypobaric hypoxia and activation of coagulation in human beings.  Lancet . 2000;  356 1657-1658
• 14 Goldhaber S Z, Grodstein F, Stampfer M J. A prospective study of risk factors for pulmonary embolism in women.  JAMA . 1997;  277 642-645
• 15 Price D T, Ridker P M. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.  Ann Intern Med . 1997;  127 895-903
• 16 Nguyen A. Prothrombin G20210A polymorphism and thrombophilia.  Mayo Clin Proc . 2000;  75 595-604
• 17 Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism.  Lancet . 2000;  356 182-183
• 18 Ridker P M, Miletich J P, Stampfer M J, Goldhaber S Z, Lindpaintner K, Hennekens C H. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism.  Circulation . 1995;  92 2800-2802
• 19 Simioni P, Prandoni P, Lensing A WA. The risk of recurrent venous thromboembolism in patients with an Arg⁵⁰⁶ ℗ Gln mutation in the gene for factor V (factor V Leiden).  N Engl J Med . 1997;  336 399-403
• 20 Margaglione M, D'Andrea G, Colaizzo D. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism.  Thromb Haemost . 1999;  82 1583-1587
• 21 De Stefano V, Martinelli I, Mannucci P M. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation.  N Engl J Med . 1999;  341 801-806
• 22 Miles J S, Miletich J P, Goldhaber S Z, Hennekens C H, Ridker P M. G20210A Mutation in the prothrombin gene and the risk of recurrent venous thromboembolism.  JACC . 2001;  37 1-4
• 23 Hankey G J, Eikelboom J W. Homocysteine and vascular disease.  Lancet . 1999;  354 407-413
• 24 Langman L J, Ray J G, Evrovski J, Yeo E, Cole D E. Hyperhomocyst(e)inemia and the increased risk of venous thromboembolism: more evidence from a case-control study.  Arch Intern Med . 2000;  160 961-964
• 25 Greaves M. Antiphospholipid antibodies and thrombosis.  Lancet. 1999;  353 1348-1353
• 26 Schulman S, Svenungsson E, Granqvist S. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group.  Am J Med . 1998;  104 332-338
• 27 Schulman S, Lindmarker P. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial.  N Engl J Med . 2000;  342 1953-1958
• 28 Chasan-Taber L, Stampfer M J. Epidemiology of oral contraceptives and cardiovascular disease.  Ann Intern Med . 1998;  128 467-477
• 29 Jick H, Kaye J A, Vasilakis-Scaramozza C, Jick S S. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995; cohort case-control analysis.  BMJ . 2000;  321 1190-1195
• 30 Rosing J, Middeldorp S, Curvers J. Low-dose oral contraceptives and acquired resistance to activated protein C: a randomized cross-over study.  Lancet . 1999;  354 2036-2040
• 31 Parkin L, Skegg D CG, Wilson M, Herbison G P, Paul C. Oral contraceptives and fatal pulmonary embolism.  Lancet . 2000;  355 2133-2134
• 32 Vandenbroucke J P, Koster T, Briët E, Reitsma P H, Bertina R M, Rosendaal F R. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.  Lancet . 1994;  344 1453-1457
• 33 Bloemenkamp K WM, Rosendaal F R, Helmerhorst F M, Vandenbroucke J P. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects.  Arch Intern Med . 2000;  160 49-52
• 34 Greer I A. Thrombosis in pregnancy: maternal and fetal issues.  Lancet . 1999;  353 1258-1265
• 35 Ray J G, Chan W S. Deep vein thrombosis during pregnancy and the puerperium: a meta-analysis of the period of risk and the leg of presentation.  Obstet Gynecol Surv . 1999;  54 265-271
• 36 Gerhardt A, Scharf R E, Beckmann M W. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.  N Engl J Med . 2000;  342 374-380
• 37 Ridker P M, Miletich J P, Buring J E. Factor V Leiden mutation as a risk factor for recurrent pregnancy loss.  Ann Intern Med . 1998;  128 1000-1003
• 38 Meinardi J R, Middeldorp S, de Kam J P. Increased risk for fetal loss in carriers of the factor V Leiden mutation.  Ann Intern Med . 1999;  130 736-739
• 39 Kupferminc M J, Eldor A, Steinman N. Increased frequency of genetic thrombophilia in women with complications of pregnancy.  N Engl J Med . 1999;  340 9-13
• 40 Brill-Edwards P, Ginsberg J S, Gent M. Safety of withholding heparin in pregnant women with a history of venous thromboembolism.  N Engl J Med . 2000;  343 1439-1444
• 41 Daly E, Vessey M P, Hawkins M M, Carson J L, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy.  Lancet . 1996;  348 977-980
• 42 Jick H, Derby L E, Myers M W, Vasilakis C, Newton K M. Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens.  Lancet . 1996;  348 981-983
• 43 Grodstein F, Stampfer M J, Goldhaber S Z. Prospective study of exogenous hormones and risk of pulmonary embolism in women.  Lancet . 1996;  348 983-987
• 44 Hulley C, Grady D, Bush T. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart Estrogen/progestin Replacement Study (HERS) Research Group.  JAMA . 1998;  280 605-613
• 45 Grady D, Wenger N K, Herrington D, for the Heart and Estrogen/progestin Replacement Study Research Group. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart Estrogen/progestin Replacement Study.  Ann Intern Med . 2000;  132 689-696
• 46 Lowe G, Woodward M, Vessey M. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.  Thromb Haemost . 2000;  83 530-535
• 47 Cummings S R, Eckert S, Krueger K A. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.  JAMA . 1999;  281 2189-2197
• 48 Fisher B, Costantino J P, Wickerham L. Tamoxifen for the prevention of breast cancer: report of the National Surgical Adjuvant Breast Bowel Project P-1 Study.  J Natl Cancer Inst . 1998;  90 1371-1388